This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's Forxiga Label Expansion Filing Accepted in EU
by Zacks Equity Research
AstraZeneca's (AZN) submission for label expansion of diabetes drug Forxiga accepted by the European Medicines Agency.
The Zacks Analyst Blog Highlights: Pfizer, Verizon, Altria, Occidental Petroleum and Community Trust
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Verizon, Altria, Occidental Petroleum and Community Trust
Glaxo's Encouraging Asthma & HIV Data at Medical Meetings
by Zacks Equity Research
Glaxo (GSK) presents data from OSMO study on a new respiratory medicine, Nucala, and on INSPIRING, a phase IIIb study on investigational HIV candidate dolutegravir at medical conferences.
What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.
Fretting Over Trump Tariffs? Buy 5 Ultra-Safe Stocks Now
by Tirthankar Chakraborty
Trump tariffs could harm global economic growth that was widely seen as the major driving force behind the stock market's rally in 2017.
5 Reasons Why Pfizer (PFE) Could be a Great Pick in 2018
by Zacks Equity Research
Pfizer's (PFE) outperformance is backed by decent quarterly results, positive news flow and regulatory updates.
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio
by Zacks Equity Research
Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
Lilly's Verzenio Wins FDA Nod for First Line Breast Cancer
by Zacks Equity Research
Lilly's (LLY) new advanced breast cancer treatment Verzenio (abemaciclib) gains FDA approval in first-line setting.
Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP
by Zacks Equity Research
CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.
Zacks.com highlights: Pfizer, Laboratory Corporation of America Holdings, Hill-Rom Holdings, HCA Healthcare and Terex
by Zacks Equity Research
Zacks.com highlights: Pfizer, Laboratory Corporation of America Holdings, Hill-Rom Holdings, HCA Healthcare and Terex
5 Best GARP Stocks Based on Discounted PEG
by Zacks Equity Research
One of the fundamental metrics for finding GARP is PEG ratio. Although it is categorized under value investing, this strategy follows the principles of both growth and value investing.
Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings?
by Zacks Equity Research
Aerie (AERI) looks poised for a beat when it reports Q4 results (due on Feb 28) on the back of lead drug Rhopressa's approval.
Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Momenta (MNTA) delivers better-than-expected fourth-quarter results on the back of an upfront payment from CSL.
Stock Market News For Feb 20, 2018
by Zacks Equity Research
Markets closed mostly higher on Friday.
Bristol-Myers Squibb (BMY) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments
by Zacks Equity Research
FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.
Exelixis Reports Positive Data From Thyroid Carcinoma Trial
by Zacks Equity Research
Exelixis (EXEl) announces positive data from a phase II trial of cabozantinib for the first-line treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma.
Merck (MRK) Halts Another Late Stage Study on Alzheimer's
by Zacks Equity Research
Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.
5 Low Leverage Stocks You Will Love on Valentine's Day
by Zacks Equity Research
Since debt-burden companies are risky to invest in, especially at times of market turmoil; risk-averse investors should go for low leverage stocks.
Pfizer Announces FDA Acceptance of NDA for NSCLC Candidate
by Zacks Equity Research
Pfizer's (PFE) regulatory applications seeking approval for tyrosine kinase inhibitor, lorlatininb, for treating second or later line NSCLC accepted in the United States, Europe and Japan.
FDA Okays J&J's Prostate Cancer Drug in First-Line Setting
by Zacks Equity Research
The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
Solid Q4 Earnings Drive Pharma ETF Outlook
by Sweta Killa
Although pharma ETFs saw terrible trading over the past one month in the latest global market rout, the string of earnings beat bolstered confidence in the space.
Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.
The Zacks Analyst Blog Highlights: CA, Quest Diagnostics, Pfizer, United Parcel and U.S. Bancorp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CA, Quest Diagnostics, Pfizer, United Parcel and U.S. Bancorp
FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up
by Zacks Equity Research
Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.